Skip to main content
Genmab logo

Genmab — Investor Relations & Filings

Ticker · GMAB ISIN · DK0010272202 LEI · 529900MTJPDPE4MHJ122 CO Manufacturing
Open in API
Filings indexed 2,823 across all filing types
Latest filing 2016-08-17 Director's Dealing
Country DK Denmark
Listing CO GMAB

About Genmab

https://www.genmab.com/

Genmab is an international biotechnology company that specializes in the creation, development, and commercialization of differentiated antibody therapeutics. The company focuses on transforming the treatment of cancer and other serious diseases. By utilizing proprietary antibody technology platforms and scientific expertise, Genmab develops a pipeline of innovative medicines. Its activities span from discovery and research through clinical development to deliver novel therapies to patients.

Recent filings

Filing Released Lang Actions
Ledende medarbejderes og deres nærtståendes transaktioner med aktier og tilknyttede værdipapirer i Genmab A/S
Director's Dealing Classification · 92% confidence The document is a company announcement under Article 19 of the EU Market Abuse Regulation listing transactions in Genmab shares by persons discharging managerial responsibilities (CEO, CFO, board member). It provides names, positions, instrument details, transaction nature, volumes, prices, dates, and is clearly reporting insider dealings. This matches the definition for Director's Dealing (Code: DIRS).
2016-08-17 English
Share Issue/Capital Change 2016
Share Issue/Capital Change Classification · 98% confidence The document is titled "Kapitalforhøjelse i Genmab som følge af udnyttelse af medarbejderwarrants" (Capital increase in Genmab due to exercise of employee warrants) and is explicitly labeled as a "Selskabsmeddelelse" (Company Announcement). It details the issuance of new shares and the resulting increase in share capital, which directly relates to financing activities and capital structure changes. This aligns perfectly with the definition for Capital/Financing Update (CAP). Although it involves shares, it is a notification about a capital change resulting from warrant exercise, not a general share repurchase (POS) or a general share issue announcement (SHA), but rather a specific financing event.
2016-08-17 English
Share Issue/Capital Change 2016
Share Issue/Capital Change Classification · 99% confidence The document is titled "Company Announcement" and details a specific corporate action: an increase in share capital resulting from the exercise of employee warrants. It specifies the number of shares issued, the subscription prices, the total proceeds, and the resulting change in total share capital. This action directly relates to changes in the company's capital structure and share count. This aligns precisely with the definition of 'Share Issue/Capital Change' (Code: SHA). It is not an earnings release (ER), an interim report (IR), or a general regulatory filing (RNS), as it concerns a specific capital event.
2016-08-17 English
Kapitalforhøjelse i Genmab som følge af udnyttelse af medarbejderwarrants
Share Issue/Capital Change Classification · 88% confidence The document is an official company announcement (“Selskabsmeddelelse”) detailing a capital increase: issuance of 347,825 new shares upon exercise of employee warrants, including subscription prices and effects on share capital. This is a direct announcement of a share issue / capital change, matching the definition of Code: SHA.
2016-08-17 Danish
Kapitalforhøjelse i Genmab som følge af udnyttelse af medarbejderwarrants
Share Issue/Capital Change Classification · 100% confidence The document is a formal company announcement regarding a capital increase resulting from the exercise of employee warrants. It details the number of shares issued, the subscription prices, and the impact on the company's total share capital. This falls directly under the definition of 'Share Issue/Capital Change' (SHA), as it describes a specific event involving the issuance of new shares and changes to the capital structure.
2016-08-17 English
Regulatory Filings 2016
Regulatory Filings Classification · 89% confidence The document is titled 'Company Announcement' and details a specific business transaction: Genmab entering a commercial license agreement with Gilead for its DuoBody® Technology. This announcement concerns a significant business development, partnership, and potential future revenue streams, but it is not a full financial report (10-K, IR), an earnings release (ER), or a proxy statement (DEF 14A). It is a specific corporate action announcement. Since the definitions do not explicitly cover 'Commercial Agreement Announcement,' I must select the closest fit. It is not a Director's Dealing (DIRS), Delisting (DLST), Dividend (DIV), or Capital Change (SHA). It is most closely related to strategic business updates. Given the options, 'Regulatory Filings' (RNS) is the general fallback for corporate announcements that don't fit specific financial reporting categories, but 'Capital/Financing Update' (CAP) is for fundraising/financing activities, which this is not directly. 'Regulatory Filings' (RNS) serves as the best general category for significant, non-standard corporate news releases that are not explicitly defined elsewhere, especially when they relate to strategic partnerships rather than core financial results or governance.
2016-08-10 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.